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Dear Editor,
We thank our colleagues for their valuable contribution
and comments on our recent article [1]. First, we
completely agree that for a thorough judgment of any
assay samples from clinically well-defined patients are
necessary. Brandenburg et al. correctly state that with the
results from the present study, it cannot be concluded
which test is the best and it is difficult to discriminate
between increased sensitivity and decreased specificity
(both leading to an increased number of positive tests).
However, this study did not aim to describe a sensitivity
for any assay for certain patient groups, nor to define the
“best test”, but to demonstrate that the results of antibody
testing for Borrelia are highly influenced by the choice of
assay. The harsh truth is that even in a country as The
Netherlands, with more than ten assays and six immuno-
blots commercially available, many potentially discrepant
results are generated every day.
The patients with skin manifestations were predominant-
ly erythema migrans patients, and the neurological patients
included only seven patients with symptoms of short
duration. We did not observe more discrepant results in
the patients with documented symptoms of short duration.
The six ELISA positive, blot negative patients were
predominantly neurological patients. In half of the patients
there was a longer disease duration, making the possibility
of an early manifestation of neuroborreliosis less likely. In
only one of these patients, a concordant result in more than
one immunoblot was present (IgG antibody reactivity in a
patient with chronic pain throughout the body). From our
data it is impossible to conclude that immunoblots are more
sensitive or less specific, and more extensive studies using
appropriate samples from patients with possible cross
reacting or aspecifically reacting samples are needed to
solve this issue.
For interpretation of Borrelia serology, clinical informa-
tion is indispensable. Part of the discrepancies between
the tests will be resolved when taking into account the
clinical picture (e.g. isolated low IgM seropositivity in a
patient with chronic complaints is suspicious for false-
positivity, even with a positive immunoblot). Recognition
of a Borrelia infection in a “typical” case of Lyme
disease (erythema migrans, monoarthritis of the knee
with a history of tick bite, etc.) will not pose a problem
in many cases and multiple studies demonstrate high
sensitivity for serological tests in these selected patient
groups. However, for clinical syndromes with a low a
priori chance of Borrelia infection (facial nerve paralysis,
sudden deafness, chronic joint pain, etc.) there is no
clinical “gold standard” and we have to rely on serological
tests.
Our samples include six patients with “definite Lyme
disease” (5 erythema migrans, 1 neuroborreliosis), 37
without Lyme disease (patients with an alternative diagno-
sis and the control patients) and 46 samples from patients
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with complaints that were compatible with Lyme disease
but not typical. For this group of patients Borrelia antibody
testing was performed in order to make a diagnosis
(“possible Lyme disease”). This last group forms the most
interesting group and the results in this group probably
illustrate our message most clearly. In 31 samples that were
tested in all eight ELISA’s and all five blots there were 24
samples from patients with “possible Lyme” (Table 1).
From these 24 patients, 12 had a positive ELISA x blot
combination and five of these 12 were positive in all 40
combinations. Therefore there were discrepancies in 7/24=
29% of these patients. However, the patients in this study
were partly selected based on reactivity in one screening
test (VIDAS) and the observed percentage discrepancies
may be overestimated.
To circumvent the problem of biased agreement due to
the inclusion of “indeterminate” results, we scored all
“indeterminate”, “grey zone” and “borderline” results as
negative. Separate agreement analysis of IgG and IgM
did not alter our conclusions. Kappa values for IgG
ranged from 0.48 to 0.94, while for IgM there was
generally less agreement with kappa’s ranging from 0.32
to 0.68 (Table 2).
In conclusion, we think that our study certainly has
limitations but our data clearly demonstrate that the
results for Borrelia antibody testing is highly influenced
by the laboratory method. The discrepancies in test
Table 1 Elisa x blot combinations per diagnosis group in 31 samples
Number of positive ELISA x blot
combinations
Definite
Lyme
Possible
Lyme
Definitely
not Lyme
0 0 12 1
1-8 0 4 1
9-23 0 1 1
24-39 2 2 0
40 2 5 0
Total number of patients 4 24 3
Table 2 IgM and IgG analyses
IgM
ELISA manufacturer Antigen used for ELISA Moran Virion/ Serion Enzygnost Euroimmun Virotech Mediphos
Moran Whole cell - - - - - -
Virion/Serion Whole cell + VlsE 0.39 - - - - -
Enzygnost Whole cell + VlsE 0.32 0.72 - - - -
Euroimmun Whole cell + VlsE 0.59 0.52 0.43 - - -
Virotech Whole cell + VlsE 0.39 0.68 0.53 0.36 - -
Mediphos Recombinant 0.59 0.44 0.34 0.68 0.44 -
IgG
ELISA
manufacturer
Antigen used for
ELISA
Moran VIDAS Virion/
Serion
Enzygnost Euroimmun Virotech Immunetics Mediphos
Moran Whole cell - - - - - - - -
VIDAS Whole cell 0.52 - - - - - - -
Virion/Serion Whole cell + VlsE 0.74 0.48 - - - - - -
Enzygnost Whole cell + VlsE 0.85 0.59 0.74 - - - - -
Euroimmun Whole cell + VlsE 0.73 0.46 0.64 0.76 - - - -
Virotech Whole cell + VlsE 0.51 0.56 0.49 0.48 0.6 - - -
Immunetics Recombinant 0.79 0.6 0.71 0.94 0.71 0.49 - -
Mediphos Recombinant 0.82 0.57 0.79 0.91 0.73 0.5 0.85 -
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results are partly resolved by taking into account clinical
data and disease duration. We applaud any initiative
aimed at increasing the availability of clinical data for
laboratories. There will always remain a substantial
group of patients in which the decision whether symp-
toms are attributable to a Borrelia infection crucially
depends on the results of serological testing. Our study
also illustrates that in this group the choice of assay
partly determines the result, and we hope that future
harmonization and standardization will minimize the
group of patients with discrepant results.
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